Skip to main content

Grafa News and Videos — Page 1154

Grafa Headlines

Latest

Grafa

Johnson & Johnson’s Tecvayli delivers superior survival outcomes in blood cancer trial

Johnson & Johnson (NYSE:JNJ) reported positive late-stage clinical data for its blood cancer therapy Tecvayli (teclistamab-cqyv), demonstrating significant improvements in survival metrics for patients with relapsed or refractory multiple myeloma.

Read more: Johnson & Johnson’s Tecvayli delivers superior survival outcomes in blood cancer trial
Grafa

Bristol Myers drug halves risk of myeloma progression in pivotal trial

Bristol Myers Squibb (NYSE:BMY) announced positive late-breaking results from its Phase 3 SUCCESSOR-2 clinical trial, demonstrating that its experimental oral therapy mezigdomide significantly extends the time patients with relapsed or refractory multiple myeloma live without their disease worsening.

Read more: Bristol Myers drug halves risk of myeloma progression in pivotal trial
Grafa

Pfizer’s Lorbrena shows historic seven-year survival advantage in lung cancer trial

Pfizer (NYSE:PFE) announced unprecedented seven-year follow-up results from its Phase 3 CROWN trial, revealing that its oncology drug Lorbrena significantly extended progression-free survival in patients with a specific, aggressive form of lung cancer.

Read more: Pfizer’s Lorbrena shows historic seven-year survival advantage in lung cancer trial
Grafa

Agios discontinues tebapivat program in lower-risk myelodysplastic syndromes after Phase 2b trial fails

Agios Pharmaceuticals (NASDAQ:AGIO) announced that it will discontinue the clinical development of its investigational oral therapy tebapivat for lower-risk myelodysplastic syndromes (LR-MDS) after a Phase 2b study failed to meet its predefined threshold for advancement.

Read more: Agios discontinues tebapivat program in lower-risk myelodysplastic syndromes after Phase 2b trial fails

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift